What is malignant hyperthermia?
Malignant hyperthermia (MH), also known as malignant hyperthermia syndrome (MHS), is a rare genetic condition that represents after the administration of general anesthetics. The treatment of this potentially fatal state is focused on immediate alleviation of episodic symptoms to prevent complications that may include organ damage and brain impair. If it is not treated, malignant hyperthermia can lead to organ failure and premature death. Such anesthetics generally administered as an inhalation can cause an increased or irregular heart rhythm as soon as the drugs enter the individual system. In most cases, the undesirable reaction is not discovered until an anesthetic is administered. Some individuals with malignant hyperthermia may develop an extremely high Tempepo anesthetic administration that requires instant application of cooling materials to reduce the fever and prevent brain damage. Other symptoms of MH include muscle rigidity and urine color resulting from impaired kidney function. Those who are diAgnostics with MHS, generally have at least one parent who is a carrier of the disease. Individuals with MH have a genetic cell mutation that causes unlimited release of calcium and potassium when exposed to certain anesthetic drugs or in some cases by physiological stress caused by extreme temperatures or extreme physical tension.
Rapid release of calcium from muscles during MH episode essentially causes muscle seizures and reinforcement and exhausts the renergy needed for proper muscle function. Lost cellular energy triggers the onset of muscle disintegration and unregulated potassium release into the bloodstream. The introduction of potassium is further enhanced by the loss of pigmentation of myoglobin released by crumbling with muscle tissues. The combination of these two adversely affects cardiovascular and renal function.
If an individual is suspected of a genetic mutation responsible for malignant hyperthermia oris aware of the family history, can undergo genetic testing to verify the presence of the Ryanodine 1 gene (Ryr1), which is responsible for the presentation of MH. Although the condition is most often diagnosed after administration of anesthetic drug, there are tests that can be carried out to evaluate the condition of the individual after its episode MH. To evaluate the condition of the muscles and control any deterioration, as stated, myoglobin urine may be performed, as is the present of myoglobin in the urine. In addition, a metabolic panel can be performed to evaluate the liver and kidney function.
MH treatment is entirely dependent on the presentation and severity of symptoms. Most individuals represent an extremely high temperature that requires immediate measures to reduce to prevent permanent organ damage. In such cases, a cool towel or blanket may be placed via individuals to reduce its body temperature. To alleviate muscle spasms and regulate the heart rhythm of the individual and regulate the srdethe rhythm of the individual and regulate the heart rhythm of the individual. Other fluids may be administered intravenously to prevent dehydration and support the proper functioning of the organs.
Malignant episodes of hyperthermia can be prevented from aware of the family history of its family history. Those with relatives who were diagnosed with MHS or died due to complications associated with Thje disorder should inform her doctor. There are anesthetic drugs that can be administered in the presence of malignant hyperthermia, which are completely safe and do not start an episode of MH, such as vecuronium, nitrous and propofol.